The iShares Nasdaq Biotechnology ETF (IBB) is the largest biotech-focused fund there is. With nearly $10 billion in assets, it is THE proxy for the biotech sector for many investors. But is it the best […]
I originally profiled the Loncar Cancer Immunotherapy ETF (CNCR) around two years ago. My general opinion at the time was that the immunotherapy category had great potential to turn into a blockbuster market, but CNCR wasn’t necessarily […]
While 2017 has been a pretty good year overall for biotechs – the two largest ETFs in the space, the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) and the SPDR S&P Biotech ETF (NYSEARCA:XBI), are up 10% […]
Momentum traders have no doubt had the healthcare equipment sector on their radar, and maybe even for some time. While the healthcare and biotech sectors were posting losses in 2016, the medical devices sector bucked […]
The biotech sector has gotten a lot of attention lately both in the financial markets and in Washington. The sector, which was one of the worst performing areas of the market in 2016 posting a […]
At the beginning of the year, I profiled the ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO). It’s a fund that is trying to carve out a unique niche in the biotechnology space by investing in those companies […]
Biotechnology stocks have soared this past year – the iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) returned an impressive 34% in 2014 – so it’s not surprising that companies are stepping up their biotech offerings in […]
Copyright © 2024 | MH Magazine WordPress Theme by MH Themes
